Randomized, multicentre, 2-dose level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody Removab (anti-EpCAM x Anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients

Trial Profile

Randomized, multicentre, 2-dose level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody Removab (anti-EpCAM x Anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2011

At a glance

  • Drugs Catumaxomab (Primary)
  • Indications Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Nov 2006 Status change
    • 29 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top